

# **SUPPLEMENTARY MATERIALS**

## **Quantitative Profiling of the Endonuclear Glycerophospholipidome of Murine Embryonic Fibroblasts**

**Emily K. Tribble<sup>1\*</sup>, Pavlina T. Ivanova<sup>2</sup>, Aby Grabon<sup>1,3</sup>, James G. Alb, Jr.<sup>1</sup>, Irene Faenza<sup>4</sup>, Lucio Cocco<sup>4</sup>, H. Alex Brown<sup>2</sup>, and Vytas A. Bankaitis<sup>1,3\*</sup>**

**<sup>1</sup>Lineberger Comprehensive Cancer Center  
University of North Carolina School of Medicine  
Chapel Hill, NC 27599-7090 U.S.A.**

**<sup>2</sup>Departments of Pharmacology and Biochemistry  
Vanderbilt University School of Medicine  
The Vanderbilt Institute of Chemical Biology  
Nashville, Tennessee 37232-6000 U.S.A.**

**<sup>3</sup>Department of Molecular and Cellular Medicine  
Texas A&M Health Science Center  
College Station, Texas 77843-1114 U.S.A.**

**<sup>4</sup>Cellular Signaling Laboratory  
Department of Biomedical Sciences  
University of Bologna, Italy**

## LEGENDS TO SUPPLEMENTAL FIGURES

**Supplemental Figure S1.** Comparative lipidomics. **(A)** Comparison of GPL composition in whole cell WT immortalized and primary MEFs. **(B)** The degree of unsaturation of PtdCho between the iMEFs and primary MEFs showed more polyunsaturated PCs in the primary cells. **(C)** The percentage of PtdEtn that is ether-linked was almost identical between iMEFs and primary MEFs. Abbreviations: PtdOH, PA; PtdCho, PC; PtdEtn, PE; PtdGro, PG; PtdSer, PS; PtdIns, PI.

**Supplemental Figure S2.** Nuclear localization patterns of PITP $\alpha$ -HA and PtdIns-binding/transfer mutants transiently overexpressed in HeLa cells. **(A)** Cells were stained with anti-HA primary antibodies 16-18 hours after transfection with PITP $\alpha$ -HA. Cells are counterstained with 4',6-diamidino-2-phenylindole (DAPI) to facilitate examination mutant constructs nuclear localization. WT constructs produce nuclear fluorescence that was greater than or equivalent to cytoplasmic fluorescence in the vast majority of expressing cells. PtdIns-binding defective point mutants, Pitp $\alpha$ <sup>T59D</sup>, Pitp $\alpha$ <sup>K61A</sup>, Pitp $\alpha$ <sup>E248K</sup> and the PtdIns/PtdCho-binding defective point mutants and Pitp $\alpha$ <sup>S166E</sup> were scored for the relative strength of nuclear signal vs. cytoplasmic fluorescence, as judged by coincidence with nuclear DAPI stain. **(B)** Quantitation of nuclear localization defects in cells expressing PITP $\alpha$ -EGFP mutant constructs. Minimally 200 cells were scored for nuclear signal  $\geq$  cytoplasmic signal (nuc  $\geq$  cyt) or if nuclear signal  $<$  cytoplasmic signal (nuc  $<$  cyt).

**Supplemental Figure S3.** Quality control analysis of *pitpa*<sup>0/0</sup> membrane-stripped nuclear fractions. (A) Immunoblot analysis of purified *PITPa*<sup>+/+</sup> and *pitpa*<sup>0/0</sup> nuclei. Lysates of membrane free nuclear fractions were compared to whole cell and cytosolic lysates for immunoreactivity to markers for cytoplasmic membrane contaminants. For calnexin and  $\beta$ -tubulin detection, ~30,000 cell equivalents of nuclear and whole cell lysate were loaded. For detection of histone H3 acetylated at lysine 9 (AcK9H3), ~100,000 cell equivalents were loaded. (B-C) Electron micrographs of membrane-stripped nuclei purified from *PITPa*<sup>+/+</sup> and *pitpa*<sup>0/0</sup> cells. Scale bars are shown: (B) 1100x magnification of *PITPa*<sup>+/+</sup> (left) and *pitpa*<sup>0/0</sup> (right) nuclei. Nuclei appear as intact particles with minimal background debris. (C) 6500x (top) and 15000x (bottom) magnification images of borders of purified *pitpa*<sup>0/0</sup> nuclei.

**Supplemental Figure S4.** Comparison of WT and *pitpa*<sup>0/0</sup> iMEF whole cell and nuclear phospholipidomes. Fractional composition of the indicated phospholipid classes in *PITPa*<sup>+/+</sup> (left) and *pitpa*<sup>0/0</sup> iMEF cells (A) and from the corresponding endonuclear fractions (B). For both panels, the values represent the averages of three independent experiments for each genotype.

**Supplemental Figure S5.** Flux of PtdIns and PtdCho into wild-type and *PITPa*<sup>0/0</sup> nuclei or whole cells. Deuterated PtdIns (A) or PtdCho (B) in whole cells as a function of time post-labeling. Data was derived from precursor scans for headgroups of *d*<sub>6</sub>-PtdIns and *d*<sub>9</sub>-PtdCho. The total deuterated PtdIns or PtdCho mass was expressed as a ratio versus total unlabeled PtdIns or PtdCho detected, respectively (triplicate determinations; \* p<0.05). Deuterated PtdIns (C) or PtdCho (D) in nuclei as a function of time post-labeling. Data was derived from precursor scans for deuterated headgroups of *d*<sub>6</sub>-PtdIns and *d*<sub>9</sub>-PtdCho. Total resulting deuterated PtdIns or

PtdCho was expressed as a percentage of total non-deuterated PtdIns or PtdCho detected, respectively, and plotted as a function of time (2, 3, 4, 6 hr) and genotype. Data represent measurement from three independent nuclear preparations for each time point combined into a single sample for each time point.



**FIG S1:**


**A** Whole WT iMEF cells




Whole WT primary MEF cells




**B** Whole WT iMEF cells: PC




Whole WT primary MEF cells: PC




**C** Whole WT iMEF cells: PE



Whole WT primary MEF cells: PE




# Fig. S2




**Fig. S3**


**A**



**B**





**C**





# Fig. S4





## A



## B



# Fig. S5



**Supplementary Table S1.**

<i>Sample</i>	<i># nuclei examined</i>	<i>% w/o membrane</i>	<i>% w/ 1 membrane patch</i>	<i>% w/ &gt;1 membrane patch</i>	<i># of membrane strands</i>
1	114	96.5	2.6	0.9	2
2	85	87.1	4.7	9.4	8
3	93	95.7	4.3	0.0	1
4	105	97.1	2.9	0.0	2
5	104	99.0	1.0	0.0	0
6	104	90.4	7.7	1.9	0
7	97	99.0	1.0	0.0	1
8	103	97.1	1.9	1.0	0
9	102	98.0	1.0	0.0	1
<b>AVG</b>	<b>101</b>	<b>95.5</b>	<b>3.0</b>	<b>1.5</b>	<b>2</b>



Supplementary Table S2.

whole MEFs				MEF nuclei			
species	mean	sem	rank	species	mean	sem	rank
PS(36:1)	301.5	44.7	1	PC(36:2)	5.2	0.7	1
PC(36:2)	250.1	17.5	2	PC(32:1)	5.1	0.5	2
PC(32:1)	195.0	12.8	3	PC(32:0)	5.0	0.5	3
PE(38:4)	146.4	14.8	4	PC(38:6)	4.9	0.5	4
PC(34:1)	142.1	8.1	5	PC(34:1)	4.3	0.5	5
PS(34:1)	122.2	10.0	6	PC(36:1)	4.1	0.5	6
PC(38:6)	108.7	14.5	7	PC(36:4)	3.8	0.6	7
PC(36:1)	102.5	25.8	8	PE(38:4)	3.7	0.5	8
PI(38:4)	97.8	18.3	9	PC(30:0)	3.5	0.4	9
PE(38:0)/PE(40:7e)/PE(40:6p)	90.4	16.1	10	PC(38:4)	3.2	0.7	10
PC(38:4)	89.5	10.7	11	PS(36:1)	2.8	0.7	11
PE(38:5e)/PE(38:4p)	89.1	5.4	12	PC(34:2)	2.5	0.5	12
PC(30:1)	86.5	32.8	13	PE(36:1)	2.2	0.2	13
PE(38:5)	84.0	11.2	14	PE(36:2)	2.0	0.3	14
PC(32:0)	83.5	6.0	15	PE(38:5e)/PE(38:4p)	1.6	0.2	15
PS(36:2)	82.7	7.4	16	PE(34:1)	1.6	0.3	16
PS(40:5)	82.7	14.7	17	PE(38:5)	1.5	0.3	17
PC(30:0)	81.7	5.1	18	PS(38:4)	1.5	0.6	18
PE(36:2)	81.0	3.8	19	PS(36:0)	1.3	0.1	19
PS(40:6)	80.9	13.0	20	PS(38:0)	1.3	0.1	20
PS(38:4)	78.2	9.6	21	PS(34:1)	1.2	0.2	21
PE(40:6e)/PE(40:5p)	77.6	8.4	22	PE(34:2e)/PE(34:1p)	1.2	0.1	22
PE(38:3)	77.2	11.2	23	PE(36:5e)/PE(36:4p)	1.1	0.1	23
PC(38:5)	75.2	11.7	24	PE(38:6)	1.0	0.2	24
PC(40:6)	75.2	10.0	25	PE(38:0)/PE(40:7e)/PE(40:6p)	1.0	0.1	25
PE(40:5e)/PE(40:4p)	74.2	11.6	26	PE(38:3)	1.0	0.2	26
PE(36:1)	67.4	4.4	27	PE(40:6)	0.9	0.1	27
PC(38:3)	67.1	8.9	28	PE(40:6e)/PE(40:5p)	0.9	0.1	28
PC(34:2)	66.4	4.6	29	PA(36:2)	0.9	0.1	29
PE(34:1)	64.6	5.8	30	PS(38:5)	0.8	0.1	30
PC(38:0)	62.6	15.8	31	PI(38:4)	0.8	0.2	31
PG(36:2)	60.8	18.3	32	PS(36:2)	0.8	0.1	32
PS(38:3)	58.5	12.8	33	PE(40:5)	0.7	0.1	33
PE(40:4e)/PE(40:3p)	58.4	12.1	34	PS(40:6)	0.7	0.1	34
PC(36:3)	56.5	4.4	35	PS(38:3)	0.7	0.1	35
PS(40:4)	56.2	11.4	36	PG(34:1)	0.7	0.2	36
PC(38:6e)/PC(38:5p)	55.9	21.1	37	PS(40:5)	0.6	0.1	37
PC(34:1e)	52.7	10.5	38	PS(40:4)	0.6	0.1	38
PG(40:7)	52.4	15.9	39	PE(40:7)	0.6	0.1	39
PC(36:0)	52.1	7.7	40	PE(40:4)	0.5	0.1	40
PC(38:2)	48.9	6.4	41	PI(38:5)	0.3	0.0	41
PC(38:5e)/PC(38:4p)	46.8	10.5	42	PI(38:3)	0.2	0.0	42
PG(34:1)	46.7	4.6	43				
PS(36:0)	45.2	15.8	44				
PE(40:6)	44.3	7.7	45				
PE(36:5e)/PE(36:4p)	43.4	3.9	46				
PE(38:1)	42.7	4.6	47				
PC(32:2)	42.3	3.2	48				
PI(38:3)	41.7	9.3	49				
PI(36:2)	39.9	6.3	50				
PC(36:4)	39.3	5.0	51				
PE(40:5)	39.2	6.8	52				

Table 2, continued.

PI(38:5)	37.8	6.7	53
PG(38:6)	37.1	23.4	54
PG(38:4)	34.4	9.3	55
PC(36:2e)/PC(36:1p)	33.4	5.4	56
PE(36:3e)/PE(36:2p)	32.2	2.4	57
PG(40:6)	31.6	12.3	58
PA(34:1)	31.1	4.6	59
PG(38:3)	30.0	8.4	60
PE(40:4)	29.2	5.0	61
PE(34:2e)/PE(34:1p)	28.6	2.4	62
PS(40:3)	28.0	8.2	63
PS(32:1)	27.6	4.2	64
PA(36:1)	26.3	4.0	65
PC(38:1)	25.9	2.9	66
PG(36:3)	25.7	5.2	67
PE(38:2)	24.2	4.8	68
PS(38:2)	22.6	3.9	69
PG(40:5)	22.2	7.3	70
PG(38:5)	22.0	5.3	71
PG(36:1)	21.7	3.6	72
PS(34:2)	21.4	2.7	73
PE(40:7)	21.4	1.8	74
PA(32:1)	19.7	3.6	75
PA(36:2)	17.3	3.1	76
PC(34:2e)/PC(34:1p)	15.6	3.3	77
PS(34:0)	15.2	4.7	78
PG(34:2)	15.0	2.2	79
PS(36:4)	14.7	1.5	80
PI(36:4)	14.5	1.6	81
PI(36:1)	13.9	3.0	82
PI(36:3)	13.8	2.2	83
PI(34:2)	13.6	1.9	84
PA(32:0)	13.0	2.4	85
PS(36:3)	12.8	1.8	86
PS(42:1)	12.8	2.6	87
PG(42:8)	12.7	4.1	88
PI(34:1)	12.6	1.7	89
PC(36:5)	12.4	0.2	90
PS(40:1)	12.3	2.0	91
PG(40:4)	12.2	3.9	92
PS(40:2)	12.0	2.4	93
PA(40:5)	11.9	2.0	94
PG(38:2)	11.9	3.4	95
PG(42:9)	10.6	3.4	96
PA(40:4)	10.5	2.3	97
PG(42:7)	10.2	3.4	98
PA(34:0)	8.9	1.9	99
PA(38:4)	8.3	1.7	100
PA(40:6)	8.0	2.5	101
PG(40:8)	7.7	2.2	102
PG(42:10)	7.7	2.4	103
PA(34:2)	7.6	1.9	104
PC(36:5e)/PC(36:4p)	7.4	0.9	105
PA(38:3)	6.9	1.3	106
PI(40:5)	6.9	1.5	107
PI(40:6)	5.4	1.2	108
PI(38:2)	5.3	1.1	109
PI(40:4)	4.9	0.8	110
PG(32:1)	3.8	0.3	111